Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): An open-label, randomised, phase 2 trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 757-766

  Glass, Bertram ^a   Hasenkamp, Justin ^b   Wulf, Gerald ^b   Dreger, Peter ^c   Pfreundschuh, Michael ^d   Gramatzki, Martin ^e   Silling, Gerda ^f   Wilhelm, Christian ^g   Zeis, Matthias ^a   Görlitz, Anke ^b   Pfeiffer, Sebastian ^b   Hilgers, Reinhard ^b   Truemper, Lorenz ^b   Schmitz, Norbert ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOGLOBIN; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DYSPNEA; DYSURIA; EDEMA; FEMALE; GASTRITIS; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INCIDENCE; INFECTION; LEUKOCYTE COUNT; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMACH ULCER; STOMATITIS; THROMBOCYTE COUNT; THROMBOSIS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84901615992     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70161-5     Document Type: Article

References (40)

1. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics: neoplasms of hematopoietic and lymphoid tissue. World Health Organization Classification of Tumours 2001, IARC Press, Lyon. P. Kleihues, L.H. Sobin (Eds.).
2. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
3. Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011, 378:1858-1867.
4. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012, 13:1250-1259.
5. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
6. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013, 31:1970-1976.
7. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667-678.
8. Chakraverty R, Mackinnon S Allogeneic transplantation for lymphoma. J Clin Oncol 2011, 29:1855-1863.
9. Van Hoef MEHM Towards a rational graft-versus-host disease (GVHD) prophylaxis: R should not be forgotten. Haematologica 2013, 98:40-41.
10. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365:1934-1941.
11. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
12. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
13. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
14. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013, 31:1530-1538.
15. Glass B, Nickelsen N, Dreger P, et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T-cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant 2004, 34:391-397.
16. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998, 92:3562-3568.
17. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999, 17:1244-1250.
19. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
21. Bauer P, Köhne K Evaluation of experiments with adaptive interim analyses. Biometrics 1994, 50:1029-1041.
22. Gray R A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1998, 16:1141-1154.
23. Ratanatharathorn V, Logan B, Wang D, et al. Prior R correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009, 145:816-824.
24. Christopeit M, Schütte V, Theurich S, et al. R reduces the incidence of acute graft-versus-host disease. Blood 2009, 113:3130-3131.
25. Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013, 122:1510-1517.
26. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
27. Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012, 119:6145-6154.
28. Tutschka PJ, Copelan EA, Klein JP Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987, 70:1382-1388.
29. Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013, 31:701-709.
30. Morgan M, Dodds A, Atkinson K, et al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991, 77:529-534.
31. van Kampen RJW, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011, 29:1342-1348.
32. Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. Blood 2012, 120:4256-4262.
33. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009, 114:1099-1109.
34. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
35. Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
36. Fürst D, Müller C, Vucinic V, et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood 2013, 122:3220. 09.
37. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
38. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
39. Chiappella A, Franceschetti S, Castellino A, et al. Final results of phase II study of lenalidomide plus rituximab-CHOP 21 in elderly untreated diffuse large B-cell lymphoma focusing on the analysis of cell of origin: REAL 07 Trial of the Fondazione Italiana Linfomi. Blood 2013, 122:850a.
40. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosin kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed / refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012, 120:686a.